Year: 2023
Type: article
Abstract: The administration of antifungals for therapeutic and, especially, prophylactic purposes is virtually a constant in patients requiring hematology-oncology treatment. Any attempt to prevent or treat Aspergillus or Mucor infections requires the administration of some drugs in the azole group, which include voriconazole, posaconazole and isavuconazole, noted for their activity against these pathogens. One very relevant aspect is the potential risk of interaction when associated with one of the antineoplastic drugs used to treat hematologic tumors, with serious complications. In this regard, acalabrutinib, bortezomib, bosutinib, carfilzomib, cyclophosphamide, cyclosporine A, dasatinib, duvelisib, gilteritinib, glasdegib, ibrutinib, imatinib, nilotinib, ponatinib, prednisone, ruxolitinib, tacrolimus, all-transretinoic acid, arsenic trioxide, venetoclax, or any of the vinca alkaloids, are very clear examples of risk, in some cases because their clearance is reduced and in others because of increased risk of QTc prolongation, which is particularly evident when the drug of choice is voriconazole or posaconazole.
Authors: José Ramón Azanza, José Mensa, José Barberán, Lourdes Vázquez, Jaime Pérez de Oteyza, Mi Kwon, Lucrecia Yáñez, José María Aguado, Antonio Cubillo Gracian, Carlos Solano, Isabel Ruiz Camps, Jesús Fortún, Miguel Salavert Lletí, Carlota Gudiol, Teresa Olave Rubio, Carolina García-Vidal, Montserrat Rovira Tarrats, María Suárez-Lledó Grande, Pedro González-Sierra, Carlos Dueñas Gutiérrez
Institutions: Clinica Universidad de Navarra, Universidad de Navarra, Hospital Clínic de Barcelona, Universidad San Pablo CEU, Complejo Hospitalario de Salamanca, Hospital General Universitario Gregorio Marañón, Universidad de Cantabria, Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla, Universidad Complutense de Madrid, Research Institute Hospital 12 de Octubre, HM Hospitales, Hospital Universitario HM Sanchinarro, Universitat de València, Hospital Clínico Universitario de Valencia, Vall d'Hebron Hospital Universitari, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Centro de Investigación Biomédica en Red Enfermedades Infecciosas, Hospital Universitari i Politècnic La Fe, Bellvitge University Hospital, Institut Català de la Salut, Hospital Clínico Universitario Lozano Blesa, Instituto de Salud Carlos III, Hospital Universitario 12 De Octubre, Fundación Josep Carreras Contra la Leucemia, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Instituto de Investigación Biosanitaria de Granada, Hospital Universitario Virgen de las Nieves, Hospital Clínico Universitario de Valladolid
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4362455669